Main Directions of Effective Influenza Prevention in Modern Conditions
https://doi.org/10.31631/2073-3046-2017-16-5-80-86
Abstract
This paper presents the risk analysis of influenza virus infection in different age groups based on the prevalence and mortality rates. The epidemiological characteristics of the influenza virus circulation during postpandemic period are given. Main aspects of specific and non-specific influenza prevention are discussed. The efficacy of the interferon-based medication Grippferon in the prevention of influenza and acute respiratory viral infections (ARVI) is justified.
About the Authors
E. I. Burtseva
D.I. Ivanovsky Institute of Virology, N.F. Gamaleya National Centre of Epidemiology and Microbiology, Ministry of Healthcare
Russian Federation
Russian Federation
E. A. Mukasheva
D.I. Ivanovsky Institute of Virology, N.F. Gamaleya National Centre of Epidemiology and Microbiology, Ministry of Healthcare
Russian Federation
Russian Federation
A. G. Rosatkevich
D.I. Ivanovsky Institute of Virology, N.F. Gamaleya National Centre of Epidemiology and Microbiology, Ministry of Healthcare
Russian Federation
Russian Federation
References
1. Vaccines against influenza. WHO position paper. Weekly epidemiological record. 2012; 47 (87): 461–476. Available at: http://www.who.int/wer/2012/wer8747/en/.
2. Kumar A., Zarychanski R., Pinto R. Cook D.J., Marshall J., Lacroix J. et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009; 302: 1872–1879.
3. Maleev V,V,, Mikhailova E,V,, Chudakova T,K,, Romanovskaya A.V., Danilov A.N., Khripunova G.I. at al. Clinical and epidemiological characteristics of influenza in the post-pandemic period. Saratovskij nauchno-medicinskij zhurnal. [Saratov Journal of Medical Scientific Research]. 2013; Т. 9 (2): 186–192 (in Russian).
4. Mikhailova E.V., Romanovskaya A.V., Salov I.A., Chudakova T.K. The problem of acute respiratory viral infection and influenza A (H1N1) in modern obstetrics. Saratovskij nauchno-medicinskij zhurnal. [Saratov Journal of Medical Scientific Research]. 2012; 8 (2): 218– 223 (in Russian).
5. L’vov D.K., Shchelkanov M.Yu., Bovin N.V., Malyshev N.A., Chuchalin A.G., Kolobukhina L.V. et al. Correlation between the receptor specificity of strains of pandemic influenza A (H1N1) virus pdm09 , isolated in 2009–2011, the structure of the receptor-binding site and the likelihood of developing lethal primary viral pneumonia. Voprosi virusologii. [Problems of Virology], 2012;.57 (1): 14–12 (in Russian).
6. Komissarov A., Fadeev A., Petrov S.,Sintsova K., Egorova A., et al. Rapid spread of influenza A(H1N1)pdm09 viruses with a new set of specific mutations in the internal genes in the beginning of 2015/2016 epidemic season in Moscow and Saint- Petersburg (Russian Federation). Influenza & Other Respiratory Viruses, 2016; 10 (4): 247–253.
7. L’vov D.K., Burtseva E.I., Kolobukhina L.V., Deryabin P.G., Kirillova E.S., Trushakova S.V. at al. Features of the epidemic season 2014/2015. on influenza in different regions of Russia. Infekcionnije bolezni. [Infectious Diseases]. 2015; 13 (4): 59–67 (in Russian).
8. Recommended composition of influenza virus vaccines for use in the 2017–2018 northern hemisphere influenza season. Weekly Epidemiological Record, 17 March 2017; 92 (11): 117 – 128. Available at: http://www.who.int/wer/2017/wer9211/en/
9. Grohskopf L.A., Olsem L.J., Sokolow L.Z., Broder K.R., Walter E.B., Bresee J.S. et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization practices (ACIP) – United states, 2014- 2015 influenza season. MMWR. 2014; 63 (32): 691–697.
10. Council of the European Committees. Proposal for a Council recommendation on seasonal influenza vaccination 2009 (cited 2016 May 27). Available at: http://ec.europa.eu/health/ph_threats/com/Influenza/docs/seasonflu_rec2009_en.pdf
11. Popova A.Y., Ezhlova E.B., Melnikova A.A., Frolova N.V., Mikheev V.N., Ryzhikov A.B. et al. Influence of annual immunization against influenza on the incidence of this infection in the population of the Russian Federation. Epidemilogia i vaccinoprofilactica. [Epidemiology and Vaccine Prevention]. 2016; 1 (86): 48–55 (in Russian).
12. Flannery B., Clippard J., Zimmerman R.K., Nowalk M.P., Jackson M.L., Jackson L.A., Early Estimates of Seasonal Influenza Vaccine Effectiveness – United States, January 2015. MMWR. 2015; 64 (01): 10–15.
13. Influenza vaccine effectiveness in the United States – 2015/16 Season. Available at: https://resident360.nejm.org/content_items/influenza-vaccineeffectiveness-in-the-united-states-2015–16-season
14. Summary of the 2015-2016 influenza season in the United States. Available at: https://www.cdc.gov/flu/about/season/flu-season-2015-2016.htm.
15. Krasnov V.V. The efficacy of recombinant interferon-alpha in the treatment and prevention of acute respiratory viral infection. Voprosi prakticheskoi pediatrii. [Clinical Practice in Pediatrics]. 2016; 11 (4): 44–52 (in Russian).
16. Panova I,A., Malyshkina A.I., Sotnikova N.Yu., Chasha T.V. Prevention of influenza and acute viral infections in pregnant and newborns. Infekcionnije bolezni. [Infectious Diseases]. 2017; 1: 32–41 (in Russian).
17. Filkina O.M., Vasilyeva T.P., Chumakov A.S., Fil’kina E.V. Prevention of acute respiratory viral infections in premature infants, including those born with very low and extremely low body weight, with interferon alpha-2b medications. Journal mezhdunarodnoi medicini. [Journal of International Medicine]. 2013; 4 (5); 97–100 (in Russian).
18. Feklisova L.V. Clinical-laboratory evaluation of the use of interferon preparations in children with acute respiratory pathology in medical and health institutions. Epidemiologiya i infektsionnye bolezni. Aktualnye voprosy. [Epidimiology and infectious diseases. Actual questions]. 2012; 1: 71–75 (in Russian).
19. Osidak L.V., Drinevsky V.P., Gaponyuk P.Ya. Grippferon. Methodological manual for medical doctors. St. Petersburg. Research Institute of Influenza; 2008: 60 (in Russian).
20. Osidak L.V. Yanina MA, Zarubaev V.V., Goncharova E.S., Alekseeva O.A. Prevention of adenovirus infection in preschool institutions with the help of recombinant interferonαalfa-2b. Detskie infekcii. [Children Infections]. 2016; 15 (2): 9 – 14 (in Russian).
21. Belokrinitskaya E., Tarbaeva D., Trubicina A. Severe forms of influenza in pregnant women: risk factors, clinical features, prevention. Vrach [The Doctor]. 2013; 3: 32–36 (in Russian).
22. Malyshkina A.I., Panova I.A., Pesikin O.N., Litsova A.O. Prevention of influenza and acute respiratory viral infections in pregnant women. Informative and methodological letter. Ivanovo.2017: 32 (in Russian).
23. Ershov F.I., Kiselev O.I. Interferons and their inducers (from molecules to medications). Moscow. REOTAR- MEDIA. 2005: 368 (in Russian).
24. Trukhan D.I., Mazurov A.L., Rechapova L.A. Acute respiratory viral infections: current issues of diagnosis, prevention and treatment in the practice of the therapist. Terapevticheskiy arkhiv. [Therapeutic archive]. 2016; 11: 76– 82 (in Russian).
25. Ushakova S., Talaev A., Chumikov O., Moiseenkov D. Evaluation of efficacy and safety of Grippferon® with loratadine in the prevention of influenza and other acute respiratory viral infections. Vrach. [Medical Doctor] 2015; 11: 1–4 (in Russian).
26. Alekseenko V.A., Zhirnova I.V. The experience of the medication Grippferon® with loratadine for the treatment and prevention of acute viral infection in patients with allergic rhinitis. Infekcionnije bolezni. Novosti. Mnenia. Obuchenie. [Infectious diseases. News. Opinions. Learning]. 2017; 11 (18): 1–8 (in Russian).
Review
For citations:
Burtseva E.I., Mukasheva E.A., Rosatkevich A.G. Main Directions of Effective Influenza Prevention in Modern Conditions. Epidemiology and Vaccinal Prevention. 2017;16(5):80-86. (In Russ.) https://doi.org/10.31631/2073-3046-2017-16-5-80-86
Views:
913
Email this article 